Doctors prescribing lecanemab for Alzheimer's disease have faced a frustrating gap since the drug reached the clinic: no reliable early signal telling them whether it's actually working for a given patient, short of waiting months to see whether cognitive decline slows down. A study published August 11, 2026, and reported by Medscape, offers a possible fix, using a blood biomarker that changes early enough to matter.

A real-world study built around routine blood draws

The research team conducted a prospective study of 153 patients treated at a tertiary referral memory clinic in Seoul, South Korea. Participants had early Alzheimer's disease, either mild cognitive impairment attributable to Alzheimer's or mild Alzheimer's dementia, along with a smaller group experiencing subjective cognitive decline, and all had confirmed underlying amyloid pathology before starting treatment. Every patient received lecanemab, sold under the brand name Leqembi, administered intravenously at 10 milligrams per kilogram every two weeks, following standard regulatory guidance and current clinical practice recommendations for the drug.

Rather than relying solely on cognitive testing to judge how patients were responding, researchers tracked plasma p-tau217, a specific form of phosphorylated tau protein detectable through a standard blood draw, at baseline, three months, and six months after treatment began, with additional measurements planned at 12 and 18 months to extend the study's tracking window further.

What the biomarker actually revealed

The results showed a clear and clinically useful pattern. Plasma p-tau217 levels decreased within three months of starting lecanemab treatment, with an even more pronounced decline occurring between the three- and six-month marks. That timing detail carries real practical weight, since it means the biomarker begins shifting well before most cognitive assessments would reliably detect any meaningful change in a patient's day-to-day functioning.

More importantly for clinical decision-making, patients who experienced larger reductions in their p-tau217 levels showed correspondingly more favorable cognitive trajectories over the study period, measured using the Korean version of the Mini-Mental State Examination, Second Edition. That correlation between an early blood biomarker change and later cognitive outcome is precisely the kind of relationship clinicians need if they want to identify which patients are genuinely benefiting from an expensive, time-intensive infusion therapy before months of treatment have already passed.

Why identifying non-responders early actually matters

Lecanemab is not a simple medication to administer or tolerate. It requires biweekly intravenous infusions, carries a documented risk of amyloid-related imaging abnormalities that require periodic MRI monitoring, and represents a substantial ongoing commitment of both a patient's time and, in many healthcare systems, considerable cost. For a treatment with that kind of burden, having no reliable way to identify early whether a given patient is actually responding, versus a patient who might reasonably consider stopping treatment or switching to a different approach, represents a genuine gap in how the drug currently gets used in practice.

The study's authors framed that gap directly in their conclusions, writing that early changes in plasma p-tau217 "may help identify responders and non-responders, enabling more individualized treatment strategies." That framing positions the biomarker not as a replacement for cognitive assessment, but as a considerably faster, less subjective complement to it, one drawn from routine blood work rather than requiring extended clinical evaluation sessions to interpret.

How this fits into a broader shift toward blood-based Alzheimer's monitoring

This Seoul-based research adds to a rapidly growing body of evidence supporting blood-based biomarkers as practical tools for Alzheimer's disease management, a shift that has accelerated considerably since anti-amyloid antibody therapies like lecanemab and donanemab reached clinical use. Separate real-world studies conducted in China have reported broadly similar findings, showing that p-tau217 reductions during lecanemab treatment tracked closely with amyloid PET clearance and correlated with improvements on cognitive assessment scales, lending independent support to the general pattern the Seoul team identified in their own patient population.

That convergence across separate patient populations and healthcare systems, Korea and multiple sites across China, strengthens confidence that the underlying biological relationship between p-tau217 decline and treatment response reflects a genuine, reproducible phenomenon rather than a pattern specific to any single clinic's patient mix or measurement methodology.

What this could mean for how lecanemab gets prescribed

If these findings hold up in larger and more diverse patient populations, plasma p-tau217 monitoring could eventually become a standard part of how clinicians manage patients on lecanemab and similar anti-amyloid therapies, offering a considerably faster way to distinguish likely responders from patients who may need a different treatment approach entirely. That kind of biomarker-guided approach would represent a meaningful step toward more genuinely individualized Alzheimer's care, moving away from a one-size-fits-all treatment protocol and toward decisions informed by how each specific patient's underlying disease biology is actually responding to therapy.

The study's authors describe their broader goal directly, writing that their findings "support the clinical utility of plasma p-tau217 as a dynamic biomarker of treatment response and may contribute to the development of biomarker-guided, individualized therapeutic" approaches going forward. With additional data collection planned out to 18 months, the research team's ongoing work should eventually clarify whether the early biomarker signal identified in this study continues predicting meaningful cognitive outcomes over a longer treatment horizon, or whether its predictive value is confined mainly to the earlier stages of treatment examined so far.

Why this matters beyond one specific drug

Beyond its direct relevance to lecanemab specifically, this study reflects a broader trend reshaping Alzheimer's clinical research and care: the move away from invasive, expensive diagnostic and monitoring tools, spinal taps for cerebrospinal fluid analysis or repeated PET imaging, toward simpler blood-based alternatives capable of delivering comparable clinical information. For a disease that already places substantial burden on patients and caregivers alike, a validated blood test capable of flagging early whether an expensive, demanding treatment is actually working represents a genuinely practical improvement to how Alzheimer's care gets delivered, not just a scientific curiosity confined to research settings.

---

*Sources cited in this article include the peer-reviewed study reported by Medscape on August 11, 2026, covering research conducted at a tertiary referral memory clinic in Seoul, South Korea, along with supporting context from related real-world lecanemab biomarker studies published in Alzheimer's & Dementia and other peer-reviewed journals. All figures reflect reporting available as of August 11, 2026.*